AURA logo

AURA BIOSCIENCES INC

AURANASDAQ
🏆 #2807 by market capUS Equity
$6.16▼ $0.00 (−0.08%)
After hours · at close
🔔
Track AURA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.1%
7d▼ 4.7%
14d▼ 11.4%
30d▼ 16.7%
ytd▲ 12.8%
1y▼ 0.2%
🏦Market Cap
$637M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$6.13 – $6.25
52-Week Range
$4.73 – $9.54
Volume
$4.80B
Avg Volume
$5.83B
Shares Outstanding
103.4M
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$88M
Last Q Revenue
$23M
P/E Ratio
-3.5
P/S Ratio
0.0x
EPS (TTM)
$-1.38
Dividend Yield
0.00%
Dilution (1yr)
+21.5%

Why Investors Own AURA

  • ✓High-growth profile — revenue up +22.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 64% gross margin and 22% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AURA logo

AURA BIOSCIENCES INC

AURA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$113M▲ +17.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$85M▲ +5.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
60.3M▲ +21.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$42M▲ +$29M YoY
StockOtter · stockotter.space

About AURA BIOSCIENCES INC

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Ratings

ⓘ
Consensus
Buy
12 analysts
Strong Buy3
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Barron’s·2h ago

AURA BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift AURA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

AURA BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.